Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study
about
sameAs
Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsStrategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer TherapeuticsComparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studiesSpecificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerBispecific digoxigenin-binding antibodies for targeted payload deliveryWorld Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.Recent trends in targeted anticancer prodrug and conjugate design.Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.Antibody-DM1 conjugates as cancer therapeutics.Antibody Drug Conjugates: Nonclinical Safety Considerations.Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.Antibody-cytotoxic agent conjugates for cancer therapy.Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical TrialsSelective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer.Anticancer carrier-linked prodrugs in clinical trials.CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Pharmacokinetic considerations for antibody drug conjugates.Optimising the delivery of tubulin targeting agents through antibody conjugation.ADME of antibody-maytansinoid conjugatesProposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake.Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug ConjugatesAntibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.In vivo biotransformations of antibody-drug conjugates.Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.Protein based therapeutic delivery agents: Contemporary developments and challenges.Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study.Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.Immunogenicity screening in protein drug development.
P2860
Q24624489-4462CC1A-1AD1-4C56-84DD-ADC94DCD788CQ26780335-9E6340B2-60CC-422E-803B-26654B6DF513Q26830923-C5519E92-2C98-4B39-B3C7-D5ADAD211981Q26853171-9C22CEF0-5F49-4B5C-86A1-B0B61FCDB01BQ27667652-74651622-F2F0-4A22-B5BF-67323CD903CBQ30414399-01F0A126-0FA1-40AD-8408-309A39E4F485Q30524836-2BECC8C6-A265-4D1F-B3D9-601A6630B0E3Q33311571-E426B6E0-3F1E-4094-919B-FD6D020237A7Q33402778-A9D1E741-2004-4A54-A62B-FFDBAACAD55CQ33409083-0F58A282-CC6F-4B87-B247-385FEF170E25Q33573762-52BF1491-D1AF-4462-AEFD-92AEA2043F82Q34162875-8B43D259-151B-4692-B388-B4F7807806FEQ34177359-A6928ED3-3E23-4FD6-AEBC-3B0CA9AC4E65Q35967917-4D3CF09F-7B54-48AB-80D8-81362BD095CCQ36200153-CE198F40-CA19-49E7-BB18-EF2D6EEBBA56Q36316831-8078DC42-D4BE-4DB4-8E25-AD02D7FDA559Q36366709-3D1D2394-4083-4B6E-8A8C-F488C7B37062Q36378949-05B0BA0D-A9E8-4AB0-9BCF-39034F6A1427Q36407249-3D0E519D-CF39-47A5-8FF8-2F9F999756E6Q36861603-FBAF8DAF-7681-4FC7-8F4A-D31DD8119E1EQ37402888-5366C05E-78E1-42A3-93D0-79A4C3CFB7B3Q37854644-9F0812B6-CE73-4D6A-BA21-D638E1224EF3Q38022192-D6080A69-E573-4B7B-8AC3-883BBEEC3852Q38024991-8CD3B802-23A0-42EE-9012-4BC31DB2E211Q38033114-C9CA8791-7C96-41B0-9236-8D9B7C76E07EQ38065955-B65E09D9-BB2F-4B74-A7F8-089A1F1C1B38Q38262066-1537D58E-085E-4DAE-B4A4-C38BBD3222D7Q38489049-CDB42B30-0818-489D-921D-01EF1CEA3B41Q38557525-8007D909-25ED-4878-BFA1-AC59EC14C736Q38798481-929D5BE0-BCF7-4A7E-B8B6-A08C77D6E299Q38817525-1C1C82BA-E831-4038-86DF-F30AFA36A839Q39273739-2230A0B2-64A0-4754-8425-65E3A534C833Q39645683-F4E57205-3799-4098-B90E-8299C60A5E1CQ40315198-80AAD29A-AF3E-4D66-9AC3-3CE33D20C963Q40677793-CF4D7A30-539A-4276-920A-C7CD51FFD140Q43096291-0A357C05-6586-4F7D-BA83-65BA1211B817Q43751494-5DBFFBCC-C17B-4D97-ACC6-894AC3C667C1Q44895959-D9C5989D-DAA9-4992-AEC3-5BBA7160E190Q47661007-6B8FF22B-FF5C-4BF8-AA01-FE88583D3017Q49168236-8D3F6934-0B03-49BD-8191-4B15CB7B867D
P2860
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@ast
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@en
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@nl
type
label
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@ast
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@en
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@nl
prefLabel
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@ast
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@en
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@nl
P2093
P3181
P356
P1476
Cantuzumab mertansine, a mayta ...... and biologic correlative study
@en
P2093
Amita Patnaik
Anthony W Tolcher
Charlene Audette
Chris Takimoto
Eric K Rowinsky
Garry Schwartz
Helen Martino
Johann de Bono
John M Lambert
P304
P3181
P356
10.1200/JCO.2003.05.137
P407
P577
2003-01-15T00:00:00Z